Stanford-StartX Fund-backed microbial diagnostics and wellness product developer UBiome has raised $83m in series C funding.

Helsinn Investment Fund and Alexandria Venture Investments both invested as MD Anderson-backed OncoResponse looks to advance five immuno-oncology drug candidates.

Twentyeight-Seven Therapeutics has officially launched with $65m in series A funding to commercialise oncology treatments based on research at Harvard Medical School.

Berkeley Catalyst Fund has helped close a $90m series B round for 4D Molecular Therapeutics, which emerged out of UC Berkeley.

Oxford Sciences Innovation has contributed to a series B round for Evox Therapeutics, a spinout of University of Oxford that has also added GV as a shareholder.

Illumina, GV and Orient Life supported a $72m series C round for MIT spinout SQZ Biotechnology, with the money set to fund therapies for solid tumours and autoimmunity.

Therachon has welcomed back Inserm Transfert Initiative for its series B round, led by Novo.

Existing shareholder IP Group has returned to back an $84m series B round for Artios, which also attracted corporates Pfizer, Novartis, AbbVie and Merck Group.

Apeel has taken its total funding to $110m after raising $70m in a series C round led by Viking Global Investors.

Utimco returned to reinvest in AgBiome, having previously backed a $34.5m series B round for the UNC spinout in 2015.